DOCSLIB.ORG

Risk of Pancreatic Adenocarcinoma in Chronic Pancreatitis D Malka, P Hammel, F Maire, P Rufat, I Madeira, F Pessione, P Lévy, P Ruszniewski

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Risk of Pancreatic Adenocarcinoma in Chronic Pancreatitis D Malka, P Hammel, F Maire, P Rufat, I Madeira, F Pessione, P Lévy, P Ruszniewski 849 PANCREATIC DISEASE Gut: first published as 10.1136/gut.51.6.849 on 1 December 2002. Downloaded from Risk of pancreatic adenocarcinoma in chronic pancreatitis D Malka, P Hammel, F Maire, P Rufat, I Madeira, F Pessione, P Lévy, P Ruszniewski ............................................................................................................................. Gut 2002;51:849–852 Background: The risk of pancreatic cancer in patients with chronic pancreatitis (CP) is difficult to assess. Previous studies, mostly case control studies or studies relying on data case registers, reported See end of article for authors’ affiliations relative risks varying from 2.3 to 18.5. ....................... Methods: We studied a prospective, single centre, medical-surgical cohort of 373 consecutive patients (322 (86%) men, median age 40 years) with proven CP (alcoholic origin 85%) and a follow up of at Correspondence to: Professor P Ruszniewski, least two years (median follow up 9.2 years; range 2.0–34.8) in order to exclude pancreatitis reveal- Service de Gastro- ing pancreatic cancer. We calculated the age and sex standardised incidence ratio (SIR) as the ratio Entérologie, Hôpital of the number of observed cases of pancreatic cancer in this cohort to the number of expected cases, Beaujon, AP-Hp, 100 as provided by the French National Cancer Register. Boulevard du Général Results: Four cases of pancreatic adenocarcinoma (1.1% of patients) were observed in 3437 patient Leclerc, F-92118 Clichy Cedex, France; years (expected number of cases 0.15; SIR 26.7, 95% confidence interval (CI) 7.3–68.3; philippe.ruszniewski@ p=0.00002). In a second analysis in which patients lost to follow up were considered to be followed bjn.ap-hop-paris.fr up until the end point without having developed pancreatic adenocarcinoma (4762 patient years), SIR Accepted for publication was 19.0 (CI 5.2–48.8; p=0.00007). 25 June 2002 Conclusion: Patients with CP have a markedly increased risk of pancreatic cancer compared with the ....................... general population. he aetiology of pancreatic cancer remains largely elusive. x ray, computed tomography scan, ultrasonography, or Smoking, the only consistent environmental risk factor, is endoscopic ultrasonography; (2) moderate to marked associated with an approximately threefold increase in pancreatic ductal lesions on endoscopic retrograde or intra- T 1 15 the risk of pancreatic cancer, and less than 5% of cases of operative pancreatography (“Cambridge” criteria) ; (3) typi- pancreatic cancer are thought to be related to familial cal histology on an adequate surgical pancreatic specimen. CP http://gut.bmj.com/ (genetic) factors.2 was considered to be due to alcohol when alcohol intake Anecdotal case reports and short case control studies have exceeded 60 g/day for at least two years in the absence of other suggested that chronic pancreatitis (CP) is a risk factor for causes; CP was considered “idiopathic” when no cause was pancreatic cancer.3–8 Recently, several studies have reinforced found. The date of clinical onset of CP was defined as the date this hypothesis.9–14 However, the risk of pancreatic cancer in when the first manifestation clearly attributable to CP patients with CP varied widely from 2.311 to 18.514 in these occurred. The diagnosis of pancreatic adenocarcinoma had to studies, raising methodological concerns. In most, the diagno- be proved in all cases by histological examination of surgical on September 28, 2021 by guest. Protected copyright. sis of pancreatic cancer (mostly without histological confirma- specimens or fine needle biopsy. Special attention was paid to tion) or pancreatitis relied on data in inpatient, cancer, or death exclude pancreatic adenocarcinoma arising on intraductal registers,10 11 13 or even on a questionnaire12; both acute papillary mucin producing tumours. pancreatitis, unspecified pancreatitis, and CP were analysed in 10–13 9–13 Study design and data collection several series ; and most studies were retrospective, began 9 9 Patients were seen as outpatients at least once a year, or in 1946, or were multicentric, leading to heterogeneity and unscheduled (as outpatients or hospitalised) when sympto- possible biases. We thus aimed to determine the risk of pancre- matic or when their disease was complicated. Special attention atic adenocarcinoma in a prospective, single centre, medical- was paid to signs or symptoms suggestive of pancreatic cancer surgical cohort of consecutive patients with proven CP. (pain, weight loss, jaundice, abdominal mass). Abdominal imaging and laboratory tests were performed when necessary. PATIENTS AND METHODS Patients were considered lost to follow up when they failed to Patients attend our institution for more than one year. Person years All consecutive patients with suspected CP attending the (that is, the observation time contributed by one patient medical and surgical gastroenterological units of our institu- followed for one year) were calculated from the date of clini- tion between 1973 and the end point of this study (July 1997), cal onset of CP,and either the end point of the study, the last who fulfilled the diagnosis criteria of CP cited below during personal contact, the date of diagnosis of pancreatic adenocar- follow up, were prospectively studied. Patients with a follow cinoma, the date of total pancreatectomy (n=4), or death. up of less than two years or a diagnosis of pancreatic cancer Data were prospectively registered on a database. established during the first two years of follow up were excluded to rule out the possibility of pancreatitis revealing pancreatic adenocarcinoma. Definitions ............................................................. The diagnosis of CP was based on one or more of the follow- Abbreviations: CP, chronic pancreatitis; SIR, standardised incidence ing three criteria: (1) pancreatic calcifications, as evidenced by ratio. www.gutjnl.com 850 Malka, Hammel, Maire, et al tion, 500 fulfilled the diagnostic criteria of CP and were Table 1 Clinical characteristics of the 373 patients prospectively studied. Among them, 127 patients (25%) with chronic pancreatitis (CP) followed up for less than two years after the onset of CP were Gut: first published as 10.1136/gut.51.6.849 on 1 December 2002. Downloaded from CP patients excluded from the present analysis. Table 1 presents the char- acteristics of the remaining 373 patients (3437 patient years). Median age at onset of CP (y) 40 (CI 17–67, range 5–86) Mean alcohol consumption of drinkers at the time of diagno- Median age at diagnosis of CP (y) 42 (CI 20–68, range 12–86) Median duration of follow up (y) 9.2 (CI 2.2–27.2, range sis of CP was 170 g/day. Mean cumulative tobacco consump- 2.0–34.8) tion of smokers at the time of diagnosis of CP was 35 pack Male (%) 322 (86) years. The causes of non-alcoholic CP were hereditary CP Alcoholic CP (%) 318 (85) (n=6), abdominal radiotherapy (n=3), inflammatory bowel Alcohol consumption (g/day)* 0 (%) 26 (7) disease (n=1), and Sjögren’s syndrome (n=1); CP was classi- <20 (%) 25 (7) fied as “idiopathic” in the remaining 40 (11%) cases. The 118 20–120 (%) 140 (40) patients (32%) lost to follow up did not differ from the >120 (%) 162 (46) remaining CP patients in their characteristics, except for a Tobacco consumption (pack years)†‡ longer duration of follow up (median follow up 10.0 years; CI 0 (%) 36 (12) <10 (%) 24 (8) 2.2–27.2; range 2.0–31.3). 10–40 (%) 159 (52) >40 (%) 88 (29) Risk of pancreatic adenocarcinoma Pancreatic calcifications (%) § 308 (83) Sixty one patients (16%) died within the follow up period: 10 Diabetes mellitus (%)§ 202 (54) patients died from liver disease, 11 from sepsis, 16 from mis- Insulin requirement (%) § 90 (24) cellaneous causes (hypoglycaemia, pulmonary embolism, Bouts of acute pancreatitis (%) § 207 (55) Pseudocysts (%) § 171 (46) tuberculosis, stroke), and seven from unknown causes. Duodenal stenosis (%) § 69 (18) Thirteen patients (3.5%) died from non-pancreatic cancer Splenic or portal vein occlusion (%) § 77 (21) (head and neck, six; liver, three; oesophagus, one; colon, one; Liver disease/cirrhosis (%) § 140 (38)/40 (11) stomach, one; bladder, one). Four patients (1.1%) died from Biliary liver disease (%) § 51 (14) pancreatic adenocarcinoma. None had a family history of Elective surgery for CP (%) § 222 (60) Uncomplicated CP (%)§¶ 42 (11) pancreatic cancer or hereditary CP (table 2). The expected Deaths (%) 61 (16) number of cases of pancreatic cancer was 0.15, yielding an SIR of 26.7 (CI 7.3–68.3; p=0.00002). The cumulative incidence of Available data for: *353 (95%) patients; †307 (82%) patients. pancreatic cancer was 1.1% at five years and 1.7% at 10 years. ‡Percentage totals exceed 100% because of rounding. §At any time during the course of CP. SIR was 19.0 (CI 5.2–48.8; p=0.00007) in a second analysis in ¶No acute pancreatitis, pseudocysts, duodenal stenosis, biliary liver which patients lost to follow up were considered to be disease, splenic or portal vein occlusion, need for pancreatic surgery, followed up until the end point without occurrence of pancre- or insulin. atic cancer (4762 patient years; expected number of cases of pancreatic cancer 0.21). Statistical analysis DISCUSSION http://gut.bmj.com/ Differences were analysed using the Student’s t test or Mann- This single centre, medical-surgical, prospective cohort study Whitney U test as necessary for continuous data and the χ2 confirms that the risk of pancreatic cancer is markedly test or Fisher’s exact test as necessary for categorical data. We increased in CP patients compared with age and sex matched used age stratified (according to five year age groups) and sex controls. We found a much higher risk than in most case con- specific data on the incidence of cancer in France (French trol studies11 12 and population based cohort studies,10 13 several National Cancer Register, period 1983–87) to determine the of which having even challenged the hypothesis of an associ- expected number of cases of pancreatic cancer in the cohort.
Load more

Recommended publications
  • Causes of Death of Cancer Patients in a Referral Hospital in Northern Iran Between 2013 and 2016
    WCRJ 2017; 4 (3): e909 CAUSES OF DEATH OF CANCER PATIENTS IN A REFERRAL HOSPITAL IN NORTHERN IRAN BETWEEN 2013 AND 2016 F. BOZORGI, A. HEDAYATIZADEH-OMRAN, R. ALIZADEH-NAVAEI, G. JANBABAEI, S. MORADI, N. SAMADAEI Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran Abstract – Objective: Cancer is a major cause of death worldwide. The first step in planning to in- crease the survival rate of cancer patients is to know the cause of death of these patients. This study aimed to investigate the causes of death in cancer patients hospitalized in Imam Khomeini hospital of Sari, Iran (a referral hospital in northern Iran). Patients and Methods: This cross-sectional study was conducted by collecting data on the caus- es of death in cancer patients who were hospitalized and passed away in Imam Khomeini hospital between 2013 and 2016 with a clinical diagnosis of cancer by an oncologist and confirmation of a pathologist. Data were collected using a questionnaire and were then analyzed by SPSS 21. Results: The most prevalent cancers were gastric, lung, breast and colon cancers and the most frequent causes of death among patients were sepsis (45.3%), carcinomatosis (16.4%), IHD (10.8%), internal bleeding (9.6%), other infections (6%) and pneumonia (3.8%). Conclusions: Infection is the most important cause of cancer deaths, while the importance of sepsis cannot be neglected. Bleeding, carcinomatosis and cardiovascular problems are also of par- ticular importance in the deaths of cancer patients. Most of cancers were related to the digestive tract, blood, and respiratory tract. A majority of these patients died from curable causes, including infection and bleeding, meaning that a large proportion of the deaths can be avoided by taking technical clinical precautions.
    [Show full text]
  • Testicular and Para-Testicular Tumors in South Western Nigeria
    Testicular and para-testicular tumors in south western Nigeria Salako A A1, *Onakpoya U U 1, Osasan SA2, Omoniyi-Esan G O 2 1Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria 2Department of Morbid Anatomy and Histopathology, Obafemi Awolowo University Teaching Hospitals Complex, Ile- Ife, Nigeria Abstract Background: Tumors of the testis and paratesticular tissues are rare, especially in men of African descent. In recent reviews however, the incidence is rising among the Caucasians and black Americans. We set out to determine the incidence in South- Western Nigeria and to examine the histopathologic variants. Methods: A retrospective study of patients who had histopathologically confirmed testicular and para-testicular tumours between 1989 and 2005 (17 years). Their records were documented at the Ife-Ijesha cancer registry which serves 4.7 million men residing in three states of South-Western Nigeria. Results: There were 26 cases of testicular and para-testicular tumors with an average incidence of 1.5 cases per year. The incidence of testicular cancer in our study was 0.55 per 100,000 population (95% CI, 0.52- 0.57) and accounted for 1.1% of all male cancers. Rhabdomyosarcomas were the most common variety (70% of the paratesticular tumors and 26.8% of all tumors of the testis). Seminomas comprised 50% of the germ cell tumors and 15.4% of all testicular tumors in this series. Conclusion: There still remains a low incidence of testis cancer in the South Western Nigeria. The reduction in the incidence of seminomas makes rhabdomyosarcomas the most predominant tumor in South Western Nigeria.
    [Show full text]
  • PAHO/WHO Publications on Cancer Prevention and Control CANCER SITUATION in the AMERICAS
    PAHO/WHO Publications on Cancer Prevention and Control Publications can be accessed on the PAHO website at: www.paho.org/cancer CANCER SITUATION IN THE AMERICAS Cancer in the Americas - Country Profiles Cancer in the Americas: Country profiles is a book that presents recent data, by country on cancer risk factors, cancer mortality, and cancer plans, policies and services. Cancer in the Americas – Basic Indicators Cancer in the Americas: Basic Indicators is a brochure illustrating cancer mortality data and the status of cancer prevention and control programs, by country. The brochure also includes a special analysis on cervical and breast cancer mortality trends in the Americas. Fact sheet series on cancer epidemiology This series of fact sheets presents information on the epidemiology of cancer, by type, for the leading cancers in the Americas. It provides visual data on cancer incidence and mortality for: breast, cervical, colorectal, prostate, stomach, and lung cancer. Fact sheet series on cancer in the Americas This series of factsheets presents key messages about the most common cancer types in the Americas, and how PAHO/WHO is working with Members States to address the problem. It includes information on: breast, cervical, colorectal and childhood cancers, as well as palliative care. Scan the code to download the publications CANCER CONTROL PLANNING National Cancer Control Programmes: Policies and Managerial Guidelines National Cancer Control Programmes: Policies and Managerial Guidelines provides guidance to public health professionals on how to plan comprehensive cancer control programs, using evidence based approaches. Cancer Control: Knowledge into Action Cancer control: Knowledge into Action is a series of cancer control program planning modules, that provides practical advice to program managers and policy -makers on how to advocate, plan and implement effective cancer control programs.
    [Show full text]
  • CURRENT OPINION Evolving Epidemiology of HIV-Associated Malignancies
    REVIEW CURRENT OPINION Evolving epidemiology of HIV-associated malignancies Meredith S. Shiels and Eric A. Engels Purpose of review The purpose of this review is to describe the epidemiology of cancers that occur at an elevated rate among people with HIV infection in the current treatment era, including discussion of the cause of these cancers, as well as changes in cancer incidence and burden over time. Recent findings Rates of Kaposi sarcoma, non-Hodgkin lymphoma and cervical cancer have declined sharply in developed countries during the highly active antiretroviral therapy era, but remain elevated 800-fold, 10-fold and four- fold, respectively, compared with the general population. Most studies have reported significant increases in liver cancer rates and decreases in lung cancer over time. Although some studies have reported significant increases in anal cancer rates and declines in Hodgkin lymphoma rates, others have shown stable incidence. Declining mortality among HIV-infected individuals has resulted in the growth and aging of the HIV-infected population, causing an increase in the number of non-AIDS-defining cancers diagnosed each year in HIV-infected people. Summary The epidemiology of cancer among HIV-infected people has evolved since the beginning of the HIV epidemic with particularly marked changes since the introduction of modern treatment. Public health interventions aimed at prevention and early detection of cancer among HIV-infected people are needed. Keywords aging, cancer, epidemiology, HIV, immunosuppression, rates INTRODUCTION been some notable changes over the 35-year course Cancer has been a major feature of the HIV epidemic of the HIV epidemic. We focus on the most common from the beginning, when cases of Kaposi sarcoma cancers that are elevated in incidence among HIV- and non-Hodgkin lymphoma (NHL) were among infected people, characterize recent trends and the first reported manifestations of what later came highlight the patterns for developed countries, to be known as AIDS [1–3].
    [Show full text]
  • Epidemiology and Diagnosis of the Pancreatic Cancer
    1130-0108/2004/96/10/714-722 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS REV ESP ENFERM DIG (Madrid) Copyright © 2004 ARÁN EDICIONES, S. L. Vol. 96. N.° 10, pp. 714-722, 2004 POINT OF VIEW Epidemiology and diagnosis of the pancreatic cancer M. Hidalgo Pascual, E. Ferrero Herrero, M. J. Castillo Fé. F. J. Guadarrama González, P. Peláez Torres and F. Botella Ballesteros Department of General and Gastrointestinal Surgery “B”. University Hospital 12 de Octubre. Madrid. Spain Hidalgo Pascual M, Ferrero Herrero E, Castillo Fé MJ, Guadar- by comparing the number of histologically confirmed cases rama González FJ, Peláez Torres P, Botella Ballesteros F. Epi- as a result of surgery, biopsy or autopsy to the number of di- demiology and diagnosis of the pancreatic cancer. Rev Esp En- agnoses. This estimate ranges from 75 to 95%. ferm Dig 2004; 96: 714-722. Age and gender INTRODUCTION Pancreatic cancer is an increasingly common condition with a diagnosis-death ratio that rises with age. Mean age at Pancreatic cancer is the fourth leading cause of cancer-re- presentation is 69.2 years in males and 69.5 years in females lated mortality in the United States. The yearly number of according to U.S. National Reports from 1973 to 1977. The newly-diagnosed patients and the yearly mortality rate are male-female ratio varies with age, as reported by a number very close together. In 1988, around 27,000 new patients of authors. Cancer-related deaths range from 2:1 in patients were detected in the United States, and nearly 24,500 of younger than 40 years of age to 1:1 in patients older than 80 these died; in 1999, 185,000 new cases were recorded, with years of age.
    [Show full text]
  • Cancer Epidemiology, Biomarkers & Prevention
    November 2006 In collaboration with the Volume 15 AACR Molecular Number 11 Cancer Epidemiology Epidemiology Group Pages 2017–2328 and the ISSN 1055-9965 American Society of Biomarkers & Prevention Preventive Oncology Editorial The Cancer Genome and Diagnostic Blood Tests. Peter Lance . .2017 CEBP Focus: Second Primary Cancers Second Cancers Are Killing Us! David S. Alberts . .2019 The Epidemiology of Second Primary Cancers. Lois B. Travis . .2020 Identifying and Screening Patients at Risk of Second Cancers. Victor G. Vogel . .2027 Chemoprevention of Second Cancers. Susan T. Mayne and Brenda Cartmel . .2033 Commentaries American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006—Enjoy the Journey: The Long and Winding Road of Chemoprevention Agent Development. Frank L. Meyskens, Jr. .2038 New Developments in the Epidemiology of Cancer Prognosis: Traditional and Molecular Predictors of Treatment Response and Survival. Christine B. Ambrosone, Timothy R. Rebbeck, Gareth J. Morgan, Kathy S. Albain, Eugenia E. Calle, William E. Evans, Daniel F. Hayes, Lawrence H. Kushi, Howard L. McLeod, Julia H. Rowland, and Cornelia M. Ulrich . .2042 Looking Farther Afield . .2047 Reviews Alleviating the Burden of Cancer: A Perspective on Advances, Challenges, and Future Directions. David Schottenfeld and Jennifer Beebe-Dimmer . .2049 A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer. Jocelyn S. Kasper and Edward Giovannucci . .2056 Gene Expression Profiling on Lung Cancer Outcome Prediction: Present Clinical Value and Future Premise. Zhifu Sun and Ping Yang . .2063 Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics. Karin Ekström Smedby, Eva Baecklund, and Johan Askling . .2069 Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic Studies.
    [Show full text]
  • Cancer Epidemiology, Prevention, and Control T32 Training Grant the Johns Hopkins Bloomberg School of Public Health Is the Recip
    Cancer Epidemiology, Prevention, and Control T32 Training Grant The Johns Hopkins Bloomberg School of Public Health is the recipient of a T32 National Research Service Award Institutional Research Grant in Cancer Epidemiology, Prevention, and Control from the National Cancer Institute (aka training grant). The training grant provides funds for training at the pre- and post- doctoral levels in 3 tracks: the etiology and prevention of cancer, the genetic epidemiology of cancer, and cancer control. At the pre-doc level, training involves pursuit of a doctorate and dissertation research; funding is usually for up to three years, which includes tuition, stipend, and individual health insurance. At the post- doctoral level, training involves research in a mentored environment; funding usually is for two years, which includes stipend and individual health insurance. At any one time, 6 doctoral students and 3 post-doctoral fellows are funded by the training grant. Slots are available only periodically and appointments typically are not aligned with the start of the academic year. Selection by the training grant Steering Committee for a slot on the training grant is highly competitive. To be eligible for support on the training grant, you must be: 1) A US citizen or Permanent Resident; 2) Committed to training and pursuing a career in the etiology and prevention of cancer, the genetic epidemiology of cancer, or cancer control; and 3) Accepted to/enrolled in a doctoral program (PhD, ScD, or DrPH) in the Department of Epidemiology or in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health (pre-docs) or have received a doctorate in epidemiology, social and behavioral sciences, or other areas appropriate for conducting research in the etiology and prevention of cancer, the genetic epidemiology of cancer, and cancer control (post-docs).
    [Show full text]
  • Histopathological Pattern of Testicular Lesion
    Journal of Pathology of Nepal (2017) Vol. 7, 1087 - 1090 cal Patholo Journal of lini gis f C t o o f N n e io p t a a l i - c 2 o 0 s 1 s 0 PATHOLOGY A N u e d p a n of Nepal l a M m e h d t i a c K al , A ad ss o oc n R www.acpnepal.com iatio bitio n Building Exhi Original Article Histopathological pattern of testicular lesion Baidya R1, Sigdel B1, Baidya NL2 1Department of Pathology, B&B Hospital, Lalitpur, Gwarko, Nepal 2Department of General Surgery, B&B Hospital, Lalitpur, Gwarko, Nepal ABSTRACT Keywords: Background: Testicular tumors are rare type of tumors affecting adolescents and young adults. The Mixed germ cell tumor; testicular tumors constitute 4th most common cause of death from neoplasm in a younger male.The Non-Hodgkin lymphoma; present study is undertaken to analyze the pattern and age wise distribution of testicular lesions in our Seminoma; hospital. Testicular tumors Materials and Methods: This was a prospective study done over a period of 4 years from November 2012 to October 2016, after taking approval of the ethics committee and informed consent from the patients. Histopathological slides were retrieved and reviewed for tumor and its subtype. Results: A total of 60 cases of testicular lesions were encountered in our study. Out of the total 60 cases,15% (9/60) were diagnosed as malignant testicular tumor. Most of these tumors were seen between 3rd and 4th decades. Germ cell tumor was the most common type (77.7%) among which seminomas (44.44%) and mixed germ cell tumors (28.57%) were most frequently encountered.
    [Show full text]
  • Cancer Burden and Control in China
    Review Article Page 1 of 8 Cancer burden and control in China Maomao Cao, Wanqing Chen National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China Contributions: (I) Conception and design: W Chen; (II) Administrative support: W Chen; (III) Provision of study materials or patients: W Chen; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: M Cao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Wanqing Chen. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Pan-JiaYuan South Lane, Chaoyang District, Beijing 100021, China. Email: [email protected]. Abstract: Cancer is one of the major health issues in China, with approximately 3,929,000 new cases and 2,338,000 deaths in 2015. Due to ageing and extended life expectancy, the cancer burden will continue to increase. Variation of geographical distribution and transition of cancer spectrum are the main characteristics of cancer in China, which, to some extent, increase the difficulty of cancer prevention and control. Since 2012, a series of measures have been taken to reduce cancer burden, such as Healthy China 2030 strategy and The Mid-term and Long-term Plan for Prevention and Treatment of Chronic Diseases in China (2017–2025). And the China Government has shifted its focus to massive screening programs in recent years. Nevertheless, some key questions are still existed. Future screening blueprint should also take into account how to improve screening scheme and construct an effective assessment methodology which is suitable to current national condition.
    [Show full text]
  • Publications by Cancer Epidemiology Services, 1980-2013
    PUBLICATIONS CANCER EPIDEMIOLOGY SERVICES / NJSCR NEW JERSEY DEPARTMENT OF HEALTH 1980-2013 REPORTS Niu X, Burger S, Pawlish K, Paddock L, Agovino, PK. Cancer Incidence and Mortality in New Jersey, 2006-2010. New Jersey Department of Health, Cancer Epidemiology Services, Trenton, New Jersey: August 2013. Niu X, Burger S, Pawlish K, Graff J. Cancer Incidence and Mortality in New Jersey, 2005-2009. New Jersey Department of Health and Senior Services, Cancer Epidemiology Services, Trenton, New Jersey: March 2012. Roche L, Niu X, Pawlish K. Cancers with Population-Based Screening Methods – Incidence, Stage at Diagnosis and Screening Prevalence. New Jersey Department of Health and Senior Services, Cancer Epidemiology Services, Trenton, New Jersey: October 2011. Niu X, Burger S, Pawlish K, Henry K, Graff J. Cancer Incidence and Mortality in New Jersey, 2004-2008. New Jersey Department of Health and Senior Services, Cancer Epidemiology Services, Trenton, New Jersey: March 2011. Niu X, Pawlish K, Burger S, Henry K, Graff J. Cancer among Asians and Pacific Islanders in New Jersey, 1990-2007. New Jersey Department of Health and Senior Services, Cancer Epidemiology Services, Trenton, New Jersey: December 2010. Agovino P. Probability of Developing Cancer for Selected Age Groups by Sex, 2004-2006 (New Jersey and U.S). New Jersey Department of Health and Senior Services, Cancer Epidemiology Services, Trenton, New Jersey: April 2010. Niu X, Burger S, Pawlish K, Henry K. Cancer Incidence and Mortality in New Jersey, 2003- 2007. New Jersey Department of Health and Senior Services, Cancer Epidemiology Services, Trenton, New Jersey: March 2010. Roche LM, Niu X, Pawlish KS, Henry KA.
    [Show full text]
  • Depressive Disorders Among Patients with Gastric Cancer in Taiwan: A
    Hu et al. BMC Psychiatry (2018) 18:272 https://doi.org/10.1186/s12888-018-1859-8 RESEARCH ARTICLE Open Access Depressive disorders among patients with gastric cancer in Taiwan: a nationwide population-based study Li-Yu Hu2,3,4, Chia-Jen Liu4,5, Chiu-Mei Yeh6,TiLu1, Yu-Wen Hu4,7, Tzeng-Ji Chen4,6, Pan-Ming Chen8, Shyh-Chyang Lee9,10 and Cheng-Ho Chang1* Abstract Background: In cancer patients, depressive disorder comorbidity is associated with greater suicide risk and poorer treatment outcomes, quality of life, and adherence to treatment. The aim of the study was to evaluate the incidence of newly-diagnosed depressive disorders after a gastric cancer diagnosis compared with a matched cohort using the National Health Insurance Research Database in Taiwan. Methods: We conducted a retrospective cohort study of 57,506 patients (28,753 patients with gastric cancer and 28,753 matched patients) selected from the National Health Insurance Research Database. Patients were observed for a maximum of 12 years to determine the incidence of newly-diagnosed depressive disorders. Also, a Cox regression analysis which included death as an independent censor was performed to identify the potentially predictive variables for developing subsequent depressive disorders following a cancer diagnosis among the patients suffering from gastric cancer. Results: The cumulative incidence of depressive disorders in the gastric cancer patients was significantly higher compared to those in the matched cohort (p < .001). The adjusted hazard ratio was 1.54 (95% confidence interval, CI = 1.39–1.70, P < .001) in the gastric cancer cohort compared with the matched cohort.
    [Show full text]
  • PAHO/WHO Publications on Cancer Prevention and Control CANCER SITUATION in the AMERICAS
    PAHO/WHO Publications on Cancer Prevention and Control Publications can be accessed on the PAHO website at: www.paho.org/cancer CANCER SITUATION IN THE AMERICAS Cancer in the Americas - Country Profiles Cancer in the Americas: Country profiles present recent data, by country on cancer risk factors, cancer mortality, and cancer plans, policies and services. Cancer in the Americas – Basic Indicators Cancer in the Americas: Basic Indicators is a brochure illustrating cancer mortality data and the status of cancer prevention and control programs, by country. The brochure also includes a special analysis on cervical and breast cancer mortality trends in the Americas. Fact sheet series on cancer epidemiology Series of fact sheets on the epidemiology of cancer, by type, for the leading cancers in the Americas. It provides visual data on cancer incidence and mortality for: breast, cervical, colorectal, prostate, stomach, and lung cancer. Fact sheet series on key messages about cancer in the Americas Series of factsheets on the key messages about the most common cancer types in the Americas, and how PAHO/WHO is working with Members States to address the problem. It includes information on: breast, cervical, colorectal and childhood cancers, as well as palliative care. Scan the code to download the publications CANCER CONTROL PLANNING National Cancer Control Programmes: Policies and Managerial Guidelines National Cancer Control Programmes: Policies and Managerial Guidelines provides guidance to public health professionals on how to plan comprehensive cancer control programs, using evidence based approaches. Cancer Control: Knowledge into Action Cancer control: Knowledge into Action is a series of cancer control program planning modules, that provides practical advice to program managers and policy -makers on how to advocate, plan and implement effective cancer control programs.
    [Show full text]